Press Releases

Press Releases

Date Title and Summary Additional Formats
Mar 16, 2020 Catalyst Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update
-Firdapse ® Q4 Net Revenues of $30 Million , FY 19 Net Revenues of $102 Million -GAAP Net Income of $32 Million for Fiscal Year 2019 -Catalyst Reiterates Net Revenue Guidance in the Range of $135 Million to $155 Million for FY 2020 -Firdapse Supply Chain in Solid Position-Significant Safety Stock
Mar 10, 2020 Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 17th, 2020
CORAL GABLES, Fla. , March 10, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
Feb 27, 2020 Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2020
CORAL GABLES, Fla. , Feb. 27, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
Feb 26, 2020 Catalyst Pharmaceuticals to Present at the Cowen 40th Annual Health Care Conference
CORAL GABLES, Fla. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
Feb 06, 2020 Catalyst Pharmaceuticals to Present at the 22nd Annual BIO CEO & Investor Conference
CORAL GABLES, Fla. , Feb. 06, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
Feb 04, 2020 Catalyst Pharmaceuticals Appoints David Ailinger as Vice President, Business Development
CORAL GABLES, Fla. , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
Jan 06, 2020 Catalyst Pharmaceuticals Pre-Announces Estimated Firdapse® Revenues and Provides Updates on Advancement of Clinical Development Programs
- Firdapse 2019 Net Product Revenues Expected to be Approximately $102 Million - Anticipates Full Year 2020 Firdapse Net Product Revenues to be in the Range of $135 million to $155 million - MuSK-MG Clinical Trial Has Met Enrollment Goals and is on Schedule to Report Top-Line Results in First Half